Erythrocin
(Erythromycin lactobionate)PreclinicalSmall molecule
PfizerErythrocin is one of 2 small molecule programs targeting Gastric. It is currently in Preclinical.
1
Indications
3
Total Trials
0
Active Trials
1
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
2 competitors in Gastric
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Type 1 Diabetes Mellitus1 trial
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
ERYTHROCIN
NDA NDA050182
Sep 24, 1986
ERYTHROCIN
NDA NDA050609
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Erythromycin lactobionate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]